Studies and reviews demonstrating the importance of HDL-C
The following studies and reviews have demonstrated the importance of HDL-C.
Alshikh-Ali AA, Abourjily HM, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the good still count? Atherosclerosis. 2005;180:217-223.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-3017.
Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (NIASPAN): a long-term study. Am J Cardiol. 1998;82:74U-81U.
Castelli WP. Cholesterol and lipids in the risk of coronary artery disease; the Framingham Heart Study. Can J Cardiol. 1988;4(Suppl A):5A-10A.
Rubins HB, Robins SJ, Colllins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
Next: Niacin Category Differences
